PhaseBio Pharmaceuticals, Inc.
4020 Aerial Center Parkway
Suite 101
Morrisville
North Carolina
27560
United States
Tel: 919-535-8861
Fax: 919-535-8867
Website: http://www.phasebio.com/
106 articles with PhaseBio Pharmaceuticals, Inc.
-
SFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio Pharmaceuticals
1/17/2023
SFJ Pharmaceuticals (“SFJ” or the “company”) today announced the closing of the sale and transfer of assets related to Bentracimab from PhaseBio Pharmaceuticals, Inc. (“PhaseBio”) to SFJ.
-
PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code
10/24/2022
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
-
PhaseBio plans to file Chapter 11 bankruptcy and sell off its bentracimab assets under a stalking horse arrangement with an unnamed “large pharmaceutical company.”
-
PhaseBio Pharmaceuticals reported its collaboration partner, SFJ Pharmaceuticals Group, informed the company it would need to return the rights to its lead program.
-
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8/12/2022
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an update on corporate activities.
-
PhaseBio is working toward mitigating the surgical risks for cardiac patients taking antiplatelet therapies with bentracimab, which is currently in Phase III development.
-
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
5/16/2022
PhaseBio Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2022, and provided an update on corporate activities.
-
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
5/16/2022
PhaseBio Pharmaceuticals, Inc. announced the completion of a successful Type B pre-biologics license application meeting with the U.S. Food and Drug Administration for bentracimab, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in patients presenting with uncontrolled bleeding or in need of surgery.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference
4/7/2022
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Financial Officer John Sharp will participate in a fireside chat at the 21st Annual Needham Healthcare Conference.
-
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
4/4/2022
PhaseBio Pharmaceuticals, Inc. today announced the complete results from its Phase 2b clinical trial of bentracimab that were presented on April 2nd during a Late Breaking Featured Clinical Research Presentation at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22).
-
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
3/24/2022
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2021, and provided an update on corporate activities.
-
PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update
3/8/2022
PhaseBio Pharmaceuticals, Inc oday announced the completion of the bentracimab drug substance and drug product Process Performance Qualification (PPQ) campaign.
-
PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference
2/24/2022
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discussion during Cowen’s 42nd Annual Health Care Conference taking place virtually on Tuesday, March 8, 2022 from 12:50 pm – 1:50 pm ET.
-
PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific Session
2/10/2022
PhaseBio Pharmaceuticals, Inc. today announced that the Phase 2b trial of bentracimab has been accepted for presentation in a Late Breaking Clinical Research session at the American College of Cardiology Annual Scientific Session & Expo being held in Washington, D.C., April 2-4, 2022.
-
PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence
12/1/2021
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), today announced the publication of the interim results from REVERSE-IT (Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial) in the New England Journal of Medicine Evidence, a new digital journal from the NEJM (New England Journal of Medicine) Group. REVERSE-IT is PhaseBio’s ongoing pivotal Phase 3 trial of its lead product bentracimab.
-
PhaseBio Names Jonathan Birchall as Chief Commercial Officer
11/18/2021
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Jonathan J. Birchall as Chief Commercial Officer.
-
If bentracimab continues to yield the desired results through the rest of the Phase III study, PhaseBio will be on track to file a Biologics License Application in mid-2022.
-
PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding
11/15/2021
PhaseBio Pharmaceuticals, Inc. today announced interim results from REVERSE-IT (Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial).
-
PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
11/10/2021
PhaseBio Pharmaceuticals, Inc. today provided an update on corporate activities and reported third-quarter 2021 financial results.